QUOTED. 27 May 2021. Jokke Mäki.
Medtech Insight spoke to three innovative diabetes companies to learn more about their technologies and how the glucose monitoring device market may be shaken up in the future. See what Jokke Mäki, CEO of GlucoModicum, said about it here.
“If you get a low-quality sample, then no matter what kind of artificial intelligence you apply, you can’t get a reading.” – Jokke Mäki, CEO, GlucoModicum
Click here for a free trial of Medtech Insight